Combined therapy with <scp>CD4</scp> <sup>+</sup> <scp>CD25highCD127</scp> <sup>−</sup> T regulatory cells and <scp>anti‐CD20</scp> antibody in recent‐onset type 1 diabetes is superior to monotherapy: Randomized phase I/ <scp>II</scp> trial - Concepedia

Concepedia

Publication | Closed Access

Combined therapy with <scp>CD4</scp> <sup>+</sup> <scp>CD25highCD127</scp> <sup>−</sup> T regulatory cells and <scp>anti‐CD20</scp> antibody in recent‐onset type 1 diabetes is superior to monotherapy: Randomized phase I/ <scp>II</scp> trial

47

Citations

19

References

2022

Year

Maciej Zieliński, Magdalena Żalińska, Dorota Iwaszkiewicz‐Grześ, Mateusz Gliwiński, Matylda Hennig, Anna Jaźwińska‐Curyłło, Halla Kamińska, Justyna Sakowska, Anna Wołoszyn‐Durkiewicz, Radosław Owczuk,

Diabetes Obesity and Metabolism

Abstract

Over 2 years, combined therapy with Tregs and rituximab was consistently superior to monotherapy in delaying T1DM progression in terms of C-peptide levels and the maintenance of remission.

References

	Year	Citations

Page 1